Table 4.
Marker levels in patients in remission at month 6, stratified by treatment
| Treatment group
|
Glucocorticoids at month 6
|
|||||
|---|---|---|---|---|---|---|
| Marker | CYC/AZA (n=60) | RTX (n=72) | p Value | Yes (n=20) | No (n=117) | p Value |
| Cytokines | ||||||
| G-CSF | 9.56 (4.67;19.6) | 11.9 (6.81;29.9) | 0.19 | 21.9 (4.03;36.6) | 10.2 (6.14;20.7) | 0.24 |
| GM-CSF | 1.38 (<0.98;4.84) | 1.08 (<0.98;8.33) | 0.72 | 1.18 (<0.98;7.66) | 1.17 (<0.98;4.68) | 0.88 |
| IFNγ | <0.49 (<0.49;<0.49) | <0.49 (<0.49;<0.49) | 0.15 | <0.49 (<0.49;<0.49) | <0.49 (<0.49;<0.49) | 0.84 |
| IL-6 | <0.49 (<0.49;0.73) | <0.49 (<0.49;0.97) | 0.35 | 0.59 (<0.49;1.18) | <0.49 (<0.49;0.73) | 0.2 |
| IL-15 | 9.93 (3.80;16.4) | 4.11 (1.77;11.1) | 0.0014* | 4.93 (2.11;13.8) | 5.69 (2.60;13.5) | 0.69 |
| IL-18 | 49.7 (27.2;83.3) | 45.7 (31.1;88.0) | 0.49 | 45.2 (28.0;128) | 52.8 (33.1;84.8) | 0.99 |
| Osteopontin | 60.4 (37.7;98.4) | 50.5 (37.2;72.9) | 0.072 | 54.4 (38.6;76.4) | 54.5 (37.6;81.9) | 0.82 |
| Chemokines | ||||||
| BCA-1 | 38.4 (23.5;60.0) | 23.9 (16.8;49.2) | 0.0053 | 64.3 (35.1;191) | 26.9 (17.1;48.2) | <0.0001* |
| IL-8 | 6.40 (3.78;13.0) | 8.33 (3.49;22.1) | 0.41 | 6.65 (1.76;24.5) | 7.23 (3.74;14.8) | 0.72 |
| IP-10 | 12.6 (7.23;25.4) | 12.9 (7.68;23.5) | 0.98 | 16.6 (6.89;30.0) | 13.1 (7.68;24.2) | 0.71 |
| RANTES | 67.0 (35.5;100) | 45.3 (29.2;84.2) | 0.08 | 62.6 (42.8;200) | 51.1 (30.2;89.5) | 0.16 |
| TARC | 555 (247;2500) | 700 (393;2500) | 0.36 | 653 (491;2161) | 655 (322;2500) | 0.58 |
| Soluble receptors | ||||||
| IL-18BP | 13.0 (6.11;42.4) | 18.4 (<6.11;65.2) | 0.5 | 12.0 (<6.11;49.3) | 16.4 (<6.11;55.7) | 0.51 |
| sIL-2Rα | <2.44 (<2.44;<2.44) | <2.44 (<2.44;<2.44) | 0.19 | <2.44 (<2.44;<2.44) | <2.44 (<2.44;<2.44) | 0.49 |
| sIL-6R | 21.2 (16.0;33.9) | 22.5 (15.2;32.8) | 0.89 | 23.0 (15.2;35.7) | 21.7 (15.5;32.4) | 0.81 |
| sTNF-RII | 2039 (1137;4009) | 2902 (1470;6569) | 0.087 | 1528 (978;3285) | 2524 (1445;5985) | 0.079 |
| Tissue damage and repair | ||||||
| ACE | 190 (127;253) | 170 (132;260) | 0.83 | 165 (142;253) | 180 (129;251) | 0.91 |
| bFGF | <0.98 (<0.98;11.6) | <0.98 (<0.98;4.53) | 0.88 | 3.15 (<0.98;21.0) | <0.98 (<0.98;3.75) | 0.16 |
| KIM-1 | 40.6 (17.3;111) | 53.9 (15.9;134) | 0.67 | 28.2 (12.8;119) | 49.3 (18.5;127) | 0.3 |
| MMP-3 | 14.9 (11.0;26.0) | 16.6 (12.9;30.5) | 0.39 | 29.3 (16.1;43.0) | 14.9 (11.6;24.0) | 0.0039 |
| NGFβ | 2.30 (0.94;4.21) | 2.71 (1.35;4.29) | 0.24 | 2.83 (0.75;7.17) | 2.35 (1.26;4.03) | 0.58 |
| PDGF-AB | 2437 (701;4814) | 3807 (1463;5864) | 0.018 | 3049 (748;3967) | 3295 (886;5610) | 0.34 |
| TIMP-1 | 169 (125;233) | 162 (129;263) | 0.9 | 212 (144;355) | 160 (125;224) | 0.078 |
| Inflammation and vascular injury | ||||||
| Clusterin | 78.3 (64.6;91.3) | 68.2 (57.5;83.8) | 0.024 | 69.4 (57.2;82.6) | 73.0 (60.0;86.8) | 0.26 |
| CRP | 0.4 (0.3;1.2) | 0.5 (0.3;1.0) | 0.78 | 0.5 (0.3;0.8) | 0.5 (0.3;1.3) | 0.77 |
| ESR | 17 (9;26) | 11 (7;21) | 0.034 | 19 (7;28) | 12 (7;22) | 0.15 |
| ICAM-1 | 461 (318;905) | 607 (356;895) | 0.25 | 786 (458;1088) | 490 (329;791) | 0.14 |
| NGAL | 169 (99.9;215) | 179 (137;287) | 0.028 | 157 (119;222) | 174 (130;243) | 0.61 |
| PAI-1 | 1200 (<977;3733) | 1645 (<977;5217) | 0.49 | 2545 (<977;5358) | 1202 (<977;3969) | 0.38 |
| VCAM-1 | 155 (116;230) | 138 (102;216) | 0.36 | 208 (126;455) | 145 (107;209) | 0.027 |
Values are median (IQR). For units, see table 1.
p<0.05 comparing groups, still significant after adjustment for multiple comparisons.
BCA-1, CXCL13; bFGF, basic fibroblast growth factor; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte–monocyte colony-stimulating factor; ICAM-1, intercellular adhesion molecule-1; IFN, interferon; IL, interleukin; IL-8, CXCL8; IL-18BP, interleukin 18 binding protein; IP-10, CXCL10; KIM-1, kidney injury molecule-1; MMP-3, matrix metalloproteinase-3; NGAL, neutrophil gelatinase-associated lipocalin; NGFβ, nerve growth factor β; PAI-1, plasminogen activator inhibitor-1; PDGF-AB, platelet-derived growth factor, A and B subunits; RANTES, CCL5; sIL-2R, soluble IL 2 receptor; sIL-6R, soluble IL 6 receptor; sTNF-RII, soluble TNF receptor II; TARC, CCL17; TIMP-1, tissue inhibitor of metalloproteinases-1; VCAM-1, vascular cell adhesion molecule-1.